Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study Oct 24, 2016 08:00AM
Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center Aug 16, 2016 08:00AM
Regen BioPharma, Inc. Files Composition of Matter Patent Application on NR2F6 Modulating Small Molecules Jul 27, 2016 08:00AM
Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company Jun 30, 2016 08:00AM
Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program Jun 16, 2016 08:00AM


Jun 14, 2016 08:30AM Regen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6
Jun 2, 2016 07:00AM Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
Jun 1, 2016 09:23AM Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB
May 24, 2016 07:00AM Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
May 19, 2016 07:00AM Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy
May 11, 2016 07:00AM Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
May 3, 2016 07:00AM Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients
Apr 28, 2016 07:00AM Regen BioPharma's HemaXellerate Therapy for Treating Aplastic Anemia Licensed for Proof of Concept Study
Apr 21, 2016 07:00AM Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
Mar 23, 2016 08:30AM Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy
Feb 24, 2016 08:30AM Regen BioPharma, Inc. Completes Preclinical Experimentation for Its siRNA NR2F6 Checkpoint Inhibitor
Feb 17, 2016 08:30AM Regen BioPharma, Inc.'s Immune Checkpoint Inhibitor Found to Stimulate Key Immune System Proteins Interleukin-17 and Interleukin-18
Feb 3, 2016 08:30AM Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors
Jan 26, 2016 08:30AM Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
Jan 20, 2016 08:30AM Regen BioPharma, Inc. and the National Institutes of Health to Collaborate
Dec 16, 2015 08:30AM Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
Dec 15, 2015 08:30AM Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate